You are here

  • Home
  • Archive
  • Volume 5, Issue 5
  • The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes

Article metrics

Article menu

Download PDFPDF

XML
Health economics
Research
The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes

 

Online download statistics by month:

Online download statistics by month: January 2018 to April 2024

AbstractFullPdf
Jan 201844403
Feb 201851414
Mar 201816516411
Apr 201842387
May 201858465
Jun 2018614910
Jul 201839392
Aug 201852523
Sep 2018737311
Oct 2018737313
Nov 2018424210
Dec 201847454
Jan 201937378
Feb 201923246
Mar 2019292311
Apr 2019464215
May 2019363013
Jun 201931319
Jul 2019343315
Aug 201914106
Oct 2019282216
Nov 201920176
Dec 201937347
Jan 202013133
Feb 2020242310
Mar 202014124
May 2020474639
Jun 2020262611
Jul 2020292312
Aug 202018185
Sep 2020252315
Oct 2020241814
Nov 20201269
Dec 2020211711
Jan 202121178
Feb 2021441
Mar 202111118
Apr 202113124
May 202117155
Jun 202112129
Jul 2021202014
Aug 2021774
Sep 2021997
Oct 20219918
Nov 2021111116
Dec 202118165
Jan 202210105
Feb 202219188
Mar 202217178
Apr 202219157
May 202291110
Jun 202213106
Jul 2022440
Aug 2022302911
Sep 20221295
Oct 202224142
Nov 2022161610
Dec 202217158
Jan 20231063
Feb 2023563
Mar 2023774
Apr 20231065
May 2023171211
Jun 2023291510
Jul 2023301910
Aug 202316105
Sep 20231392
Oct 202327262
Nov 202319163
Dec 202324186
Jan 20241032
Feb 202411102
Mar 2024191411
Apr 202420123
Total19441730589